Dr. Jordi Remon, Longarts, Gustave Roussy

💬Biography
Dr Remon is medical oncologist at Gustave Roussy, He is also the Chair of the EORTC Lung Cancer Group

🎤 Summary
Antibody–drug conjugates (ADCs) represent a rapidly advancing therapeutic strategy in lung cancer, combining the specificity of monoclonal antibodies with the potent cytotoxicity of chemotherapeutic agents. ADCs consist of three key components: a monoclonal antibody targeting a tumor-associated antigen, a cytotoxic payload, and a linker that controls drug release.

Despite the inital hope, the efficacy of ADC in advanced NSCLC is mainly driven for tuors harboring genomic alterations or with specific predictive biomarkers such as MET overexprssion.   For example, trastuzumab deruxtecan (T-DXd) targets HER2 and has shown significant responses in HER2-mutant NSCLC., whereas an ADC anti TROP2 in osimertiib resitnat tumors provided beneft in patients outcomes comapred to chemotherapy in EGFR-mutant tumors.

Challenges remain, including antigen heterogeneity, acquired resistance, and treatment-related toxicities such as interstitial lung disease. Ongoing trials aim to optimize patient selection, improve linker stability, and explore rational combinations with immunotherapy or kinase inhibitors. Overall, ADCs represent a transformative approach for lung cancer treatment, offering renewed hope for precision oncology by bridging targeted therapy and cytotoxic chemotherapy.